Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France

BMC Pediatrics

Catherine Rumeau-Pichon¹  Françoise F Hamers¹ 

[1]Department of Economic and Public Health Evaluation, Haute Autorité de Santé (HAS), 2 avenue du Stade de France, Saint-Denis, France

关键词: France;    Tandem mass spectrometry;    Health policy;    Neonatal screening;    Cost effectiveness;    Medium-chain Acyl-CoA dehydrogenase deficiency;   

Others  :  1170785
DOI  :  10.1186/1471-2431-12-60

 received in 2012-01-10, accepted in 2012-06-08,  发布年份 2012

【 摘 要 】

Background

Five diseases are currently screened on dried blood spots in France through the national newborn screening programme. Tandem mass spectrometry (MS/MS) is a technology that is increasingly used to screen newborns for an increasing number of hereditary metabolic diseases. Medium chain acyl-CoA dehydrogenase deficiency (MCADD) is among these diseases. We sought to evaluate the cost-effectiveness of introducing MCADD screening in France.

Methods

We developed a decision model to evaluate, from a societal perspective and a lifetime horizon, the cost-effectiveness of expanding the French newborn screening programme to include MCADD. Published and, where available, routine data sources were used. Both costs and health consequences were discounted at an annual rate of 4%. The model was applied to a French birth cohort. One-way sensitivity analyses and worst-case scenario simulation were performed.

Results

We estimate that MCADD newborn screening in France would prevent each year five deaths and the occurrence of neurological sequelae in two children under 5 years, resulting in a gain of 128 life years or 138 quality-adjusted life years (QALY). The incremental cost per year is estimated at €2.5 million, down to €1 million if this expansion is combined with a replacement of the technology currently used for phenylketonuria screening by MS/MS. The resulting incremental cost-effectiveness ratio (ICER) is estimated at €7 580/QALY. Sensitivity analyses indicate that while the results are robust to variations in the parameters, the model is most sensitive to the cost of neurological sequelae, MCADD prevalence, screening effectiveness and screening test cost. The worst-case scenario suggests an ICER of €72 000/QALY gained.

Conclusions

Although France has not defined any threshold for judging whether the implementation of a health intervention is an efficient allocation of public resources, we conclude that the expansion of the French newborn screening programme to MCADD would appear to be cost-effective. The results of this analysis have been used to produce recommendations for the introduction of universal newborn screening for MCADD in France.

【 授权许可】

   
2012 Hamers and Rumeau-Pichon; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Sander S, Janzen N, Janetzky B, Scholl S, Steuerwald U, Schafer J, Sander J: Neonatal screening for medium chain acyl-CoA deficiency: high incidence in Lower Saxony (northern Germany). Eur J Pediatr 2001, 160(5):318-319.
• [2]Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann GF: Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 2003, 111(6 Pt 1):1399-1406.
• [3]Maier EM, Liebl B, Roschinger W, Nennstiel-Ratzel U, Fingerhut R, Olgemoller B, Busch U, Krone N, v Kries R, Roscher AA: Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. Hum Mutat 2005, 25(5):443-452.
• [4]Derks TG, Boer TS, van Assen A, Bos T, Ruiter J, Waterham HR, Niezen-Koning KE, Wanders RJ, Rondeel JM, Loeber JG, et al.: Neonatal screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in The Netherlands: the importance of enzyme analysis to ascertain true MCAD deficiency. J Inherit Metab Dis 2008, 31(1):88-96.
• [5]la Marca G, Malvagia S, Casetta B, Pasquini E, Donati MA, Zammarchi E: Progress in expanded newborn screening for metabolic conditions by LC- MS/MS in Tuscany: update on methods to reduce false tests. J Inherit Metab Dis 2008, 31(Suppl 2):S395-S404.
• [6]Kasper DC, Ratschmann R, Metz TF, Mechtler TP, Möslinger D, Konstantopoulou V, Item CB, Pollak A, Herkner KR: The national austrian newborn screening program - eight years experience with mass spectrometry. past, present, and future goals. Wien Klin Wochenschr 2010, 122:607-613.
• [7]Shortland G, Besmey J: Newborn screening for medium-chain acyl-CoA dehydrogenase defociency (MCADD): findings from a multicentre prospective UK Collaborative study (abstract). J Inherit Metab Dis 2010, 29(Suppl 1):19.
• [8]Vilarinho L, Rocha H, Sousa C, Marcao A, Fonseca H, Bogas M, Osorio RV: Four years of expanded newborn screening in Portugal with tandem mass spectrometry. J Inherit Metab Dis 2010.
• [9]Bodamer OA, Hoffmann GF, Lindner M: Expanded newborn screening in Europe 2007. J Inherit Metab Dis 2007, 30(4):439-444.
• [10]Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, Nicholl J, Nicholson P, Tunaley JR, Virdi NK: Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997., 1(7)
• [11]Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, Littlejohns P, Lord J, Wilcox AH: Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess 1997., 1(11)
• [12]Medical Advisory Secretariat: Neonatal screening of inborn errors of metabolism using tandem mass spectrometry: an evidence-based analysis. Ontario Heath Technology Assessment Series 2003., 3(3)
• [13]Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S: Clinical effectiveness and costeffectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic eview (+annexes). Health Technol Assess 2004., 8(12)
• [14]Autti-Ramo I, Makela M, Sintonen H, Koskinen H, Laajalahti L, Halila R, Kaariainen H, Lapatto R, Nanto-Salonen K, Pulkki K, et al.: Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland. Acta Paediatr 2005, 94(8):1126-1136.
• [15]van der Hilst CS, Derks TG, Reijngoud DJ, Smit GP, TenVergert EM: Cost- effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands. J Pediatr 2007, 151(2):115-120. 120
• [16]Agence d’évaluation des technologies et des modes d’intervention en santé: Spectrométrie de masse en tandem et dépistage des erreurs innées du métabolisme. Rapport technique. AETMIS, Montreal; 2007.
• [17]Wilcken B, Haas M, Joy P, Wiley V, Chaplin M, Black C, Fletcher J, McGill J, Boneh A: Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 2007, 369(9555):37-42.
• [18]Schoen EJ, Baker JC, Colby CJ, To TT: Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics 2002, 110(4):781-786.
• [19]Insinga RP, Laessig RH, Hoffman GL: Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr 2002, 141(4):524-531.
• [20]Venditti LN, Venditti CP, Berry GT, Kaplan PB, Kaye EM, Glick H, Stanley CA: Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics 2003, 112(5):1005-1015.
• [21]Tran K, Banerjee S, Li H, Noorani HZ, Mensinkai S, Dooley K: Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. Clin Biochem 2007, 40(3–4):235-241.
• [22]Cipriano LE, Rupar CA, Zaric GS: The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. Value Health 2007, 10(2):83-97.
• [23]Prosser LA, Kong CY, Rusinak D, Waisbren SL: Projected costs, risks, and benefits of expanded newborn screening for MCADD. Pediatrics 2010, 125(2):e286-e294.
• [24]Norman R, Haas M, Wilcken B: International perspectives on the cost- effectiveness of tandem mass spectrometry for rare metabolic conditions. Health Policy 2009, 89(3):252-260.
• [25]Grosse SD: Cost effectiveness as a criterion for newborn screening policy decisions. In Ethics and newborn genetic screening: new technologies, new challenges. Edited by Baily MA, Murray TH. Johns Hopkins University Press, Baltimore; 2009:58-88.
• [26]Haute Autorité de Santé: Choix méthodologiques pour l’évaluation éconmique à la HAS. HAS, Saint-Denis La Plaine; 2011.
• [27]Haute Autorité de Santé: Evaluation a priori de l’extension du dépistage néonatal à une ou plusieurs erreurs innées du métabolisme par la technique de spectrométrie de masse en tandem en population générale en France. 1er volet: dépistage du déficit en MCAD. HAS, Saint-Denis La Plaine; 2011.
• [28]Wilcken B, Wiley V, Hammond J, Carpenter K: Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003, 348(23):2304-2312.
• [29]Chace DH, Hillman SL, Van Hove JL, Naylor EW: Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997, 43(11):2106-2113.
• [30]Carpenter K, Wiley V, Sim KG, Heath D, Wilcken B: Evaluation of newborn screening for medium chain acyl-CoA dehydrogenase deficiency in 275 000 babies. Arch Dis Child Fetal Neonatal Ed 2001, 85(2):F105-F109.
• [31]Pourfarzam M, Morris A, Appleton M, Craft A, Bartlett K: Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet 2001, 358(9287):1063-1064.
• [32]Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, Strauss AW, Comeau AM, Eaton RB, Grady GF: Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem 2001, 47(11):1945-1955.
• [33]Frazier DM, Millington DS, McCandless SE, Koeberl DD, Weavil SD, Chaing SH, Muenzer J: The tandem mass spectrometry newborn screening experience in North Carolina: 1997–2005. J Inherit Metab Dis 2006, 29(1):76-85.
• [34]Feuchtbaum L, Lorey F, Faulkner L, Sherwin J, Currier R, Bhandal A, Cunningham G: California’s experience implementing a pilot newborn supplemental screening program using tandem mass spectrometry. Pediatrics 2006, 117(5 Pt 2):S261-S269.
• [35]Hsu HW, Zytkovicz TH, Comeau AM, Strauss AW, Marsden D, Shih VE, Grady GF, Eaton RB: Spectrum of medium-chain acyl-CoA dehydrogenase deficiency detected by newborn screening. Pediatrics 2008, 121(5):e1108-e1114.
• [36]Horvath GA, Davidson AG, Stockler-Ipsiroglu SG, Lillquist YP, Waters PJ, Olpin S, Andresen BS, Palaty J, Nelson J, Vallance H: Newborn screening for MCAD deficiency: experience of the first three years in British Columbia, Canada. Can J Public Health 2008, 99(4):276-280.
• [37]Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ: The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med 2006, 8(4):205-212.
• [38]Touma EH, Charpentier C: Medium chain acyl-CoA dehydrogenase deficiency. Arch Dis Child 1992, 67(1):142-145.
• [39]Wilcken B, Hammond J, Silink M: Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency. Arch Dis Child 1994, 70(5):410-412.
• [40]Iafolla AK, Thompson RJ, Roe CR: Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 1994, 124(3):409-415.
• [41]Pollitt RJ, Leonard JV: Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. Arch Dis Child 1998, 79(2):116-119.
• [42]Klose DA, Kolker S, Heinrich B, Prietsch V, Mayatepek E, von Kries R, Hoffmann GF: Incidence and short-term outcome of children with symptomatic presentation of organic acid and fatty acid oxidation disorders in Germany. Pediatrics 2002, 110(6):1204-1211.
• [43]Derks TG, Reijngoud DJ, Waterham HR, Gerver WJ, van den Berg MP, Sauer PJ, Smit GP: The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: clinical presentation and outcome. J Pediatr 2006, 148(5):665-670.
• [44]Wilcken B, Haas M, Joy P, Wiley V, Bowling F, Carpenter K, Christodoulou J, Cowley D, Ellaway C, Fletcher J, et al.: Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 2009, 124(2):e241-e248.
• [45]Waisbren SE, Albers S, Amato S, Ampola M, Brewster TG, Demmer L, Eaton RB, Greenstein R, Korson M, Larson C, et al.: Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 2003, 290(19):2564-2572.
• [46]Dezateux C: Newborn screening for medium chain acyl-CoA dehydrogenase deficiency: evaluating the effects on outcome. Eur J Pediatr 2003, 162(Suppl 1):S25-S28.
• [47]Strauss D, Eyman RK: Mortality of people with mental retardation in California with and without Down syndrome, 1986–1991. Am J Ment Retard 1996, 100(6):643-653.
• [48]Abadie V, Berthelot J, Feillet F, Maurin N, Mercier A, Ogier de Baulny H, de Parscau L: Neonatal screening and long-term follow-up of phenylketonuria: the French database. Early Hum Dev 2001, 65:149-158.
• [49]Chace DH, Sherwin JE, Hillman SL, Lorey F, Cunningham GC: Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours. Clin Chem 1998, 44(12):2405-2409.
• [50]Ceglarek U, Muller P, Stach B, Buhrdel P, Thiery J, Kiess W: Validation of the phenylalanine/tyrosine ratio determined by tandem mass spectrometry: sensitive newborn screening for phenylketonuria. Clin Chem Lab Med 2002, 40(7):693-697.
• [51]Wilcken B: Recent advances in newborn screening. J Inherit Metab Dis 2007, 30(2):129-133.
• [52]Wilcken B: More on medium-chain acyl-coenzyme a dehydrogenase deficiency in a neonate. N Engl J Med 2008, 358(6):647.
• [53]Bras MA, Pégaz-Blanc O, Di Franco M, Kocoglu D, Martial F, Roosz P, Tronyo J, Cotis JP, de Peretti G: Tableaux de l’économie française. Institut national de la statistique et des études économiques, In. Paris; 2010.
• [54]Prosser LA, Ladapo JA, Rusinak D, Waisbren SE: Parental tolerance of false-positive newborn screening results. Arch Pediatr Adolesc Med 2008, 162(9):870-876.
• [55]Association française pour le dépistage et la prévention des handicaps de l’enfant: Bilan d’activité. AFDPHE, Paris; 2009.
• [56]Nasser M, Javaheri H, Fedorowicz Z, Noorani Z: Carnitine supplementation for inborn errors of metabolism. Cochrane Database Syst Rev 2009., (2)
• [57]National Institute for Health and Clinical Excellence: Social value judgements. Principles for the development of NICE guidance. NICE, London; 2008.
• [58]Sorenson C: The role of HTA in coverage and pricing decisions: A cross- country comparison. Euro Observer 2009, 11(1):1-4.
• [59]Poley MJ, Stolk EA, Brouwer WBF: The use and impact of HTA in decision making in the Netherlands. Euro Observer 2009, 11(1):7-8.
• [60]WHO Commission on Macroeconomics and Health: Macroeconomics and health: investing in health for economic development. World Health Organization, Geneva; 2001.